Denali Therapeutics Inc. [NASDAQ: DNLI] surged by $4.08 during the normal trading session on Monday and reaching a high of $36.12 during the day while it closed the day at $36.07. The company report on August 7, 2020 that Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights.
Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2020 and provided business highlights.
“We are thrilled with the strong progress across our pipeline, the continued productivity across the company despite the current situation imposed by the COVID-19 pandemic, and a new collaboration with Biogen on our LRRK2 program for Parkinson’s disease patients and certain TV-enabled programs,” said Ryan Watts, Ph.D., CEO. “I am particularly excited that our first therapeutic candidate leveraging our proprietary blood-brain barrier crossing TV technology platform has entered clinical studies in patients. We believe the TV platform could transform the treatment of neurological disease.”.
Denali Therapeutics Inc. stock has also gained 16.88% of its value over the past 7 days. However, DNLI stock has inclined by 40.57% in the 3 months of the year. Over the past six months meanwhile, it has gained 154.01% and gained 107.06% year-on date.
The market cap for DNLI stock reached $3.83 billion, with 105.72 million shares outstanding and 97.28 million shares in the current float. Compared to the average trading volume of 700.02K shares, DNLI reached a trading volume of 2142115 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Denali Therapeutics Inc. [DNLI]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DNLI shares is $29.73 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DNLI stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
JP Morgan have made an estimate for Denali Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on September 14, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $28 to $45. The new note on the price target was released on August 20, 2020, representing the official price target for Denali Therapeutics Inc. stock. Previously, the target price had yet another raise to $20, while Evercore ISI analysts kept a Outperform rating on DNLI stock.
The Average True Range (ATR) for Denali Therapeutics Inc. is set at 2.19, with the Price to Sales ratio for DNLI stock in the period of the last 12 months amounting to 138.36. The Price to Book ratio for the last quarter was 7.59, with the Price to Cash per share for the same quarter was set at 5.17.
DNLI stock trade performance evaluation
Denali Therapeutics Inc. [DNLI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 16.88. With this latest performance, DNLI shares gained by 20.88% in over the last four-week period, additionally plugging by 154.01% over the last 6 months – not to mention a rise of 91.66% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DNLI stock in for the last two-week period is set at 69.69, with the RSI for the last a single of trading hit 76.54, and the three-weeks RSI is set at 66.67 for Denali Therapeutics Inc. [DNLI]. The present Moving Average for the last 50 days of trading for this stock 28.78, while it was recorded at 32.43 for the last single week of trading, and 23.44 for the last 200 days.
Denali Therapeutics Inc. [DNLI]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Denali Therapeutics Inc. [DNLI] shares currently have an operating margin of -793.48. Denali Therapeutics Inc.’s Net Margin is presently recorded at -740.74.
Return on Total Capital for DNLI is now -41.74, given the latest momentum, and Return on Invested Capital for the company is -39.11. Return on Equity for this stock declined to -41.97, with Return on Assets sitting at -32.52. When it comes to the capital structure of this company, Denali Therapeutics Inc. [DNLI] has a Total Debt to Total Equity ratio set at 18.37. Additionally, DNLI Total Debt to Total Capital is recorded at 15.52, with Total Debt to Total Assets ending up at 13.11. Long-Term Debt to Equity for the company is recorded at 17.44, with the Long-Term Debt to Total Capital now at 14.73.
Reflecting on the efficiency of the workforce at the company, Denali Therapeutics Inc. [DNLI] managed to generate an average of -$757,142 per employee. Receivables Turnover for the company is 6.24 with a Total Asset Turnover recorded at a value of 0.04.Denali Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.60 and a Current Ratio set at 9.60.
Earnings per share (EPS) analysis for Denali Therapeutics Inc. [DNLI] stock
With the latest financial reports released by the company, Denali Therapeutics Inc. posted -0.48/share EPS, while the average EPS was predicted by analysts to be reported at -0.56/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 14.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DNLI.
Denali Therapeutics Inc. [DNLI]: Insider Ownership positions
There are presently around $3,000 million, or 89.80% of DNLI stock, in the hands of institutional investors. The top three institutional holders of DNLI stocks are: CRESTLINE MANAGEMENT, LP with ownership of 13,644,881, which is approximately -12.352% of the company’s market cap and around 2.60% of the total institutional ownership; BAILLIE GIFFORD & CO, holding 9,279,194 shares of the stock with an approximate value of $334.7 million in DNLI stocks shares; and FLAGSHIP PIONEERING INC., currently with $287.85 million in DNLI stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Denali Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 86 institutional holders increased their position in Denali Therapeutics Inc. [NASDAQ:DNLI] by around 7,412,298 shares. Additionally, 46 investors decreased positions by around 4,177,378 shares, while 30 investors held positions by with 71,594,943 shares. The mentioned changes placed institutional holdings at 83,184,619 shares, according to the latest SEC report filing. DNLI stock had 31 new institutional investments in for a total of 1,238,337 shares, while 10 institutional investors sold positions of 185,567 shares during the same period.